This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Dr. Guasp et al. assessed the performance of serum neurofilament light chain (NfL) testing in differentiating anti-NMDA receptor encephalitis (NMDARe) from psychiatric causes of a first episode of psychosis (pFEP) in an observational study of 118 patients with NMDARe (33 of whom had isolated psychosis at presentation), comparing them with 45 patients with pFEP, 36 patients with herpes simplex encephalitis (HSV), and 36 healthy controls. They found that young patients with first episode psychosis and serum NfL ≥15 pg/mL had a 120 times higher chance of having NMDARe than pFEP, with this cutoff correctly classifying 96% of patients with pFEP and 85% of patients with NMDARe and isolated psychosis. Notably, all patients with HSV also had serum NFL≥15 pg/mL. The authors concluded that patients with first episodes of psychosis of unclear etiology and serum NfL ≥15 pg/mL should undergo testing for NMDAR antibodies in the CSF. In response, Dr. Vale notes that the presence of NMDAR antibodies is not essential for diagnosing autoimmune encephalitis, given that other autoantibodies can cause psychotic presentations, and that elevations of NfL may reflect comorbidities causing central or peripheral neuroaxonal damage. Dr. Vale argues that given the severity of first episodes of psychosis, all such patients should be considered for CSF examinations, as was the historical practice for concerns of neurosyphilis. Responding to these comments, the authors agree that CSF studies should be reincorporated in the evaluation of patients with new onset psychosis, but note that they restricted their study to the identification of NMDARe, given that this condition can almost perfectly mimic psychiatric causes of first episodes of psychosis, in contrast to other autoimmune encephalitides, which typically have other concurrent neurologic features. They argue that the usefulness of serum NfL testing seen in their study is a relevant finding, regardless of any other underlying contributors to NfL elevation. This exchange highlights the importance of ongoing research into noninvasive markers of neurologic causes of psychosis. It is the editors' opinion that in practice, routine CSF testing for all patients with first episodes of psychosis is unlikely to be feasible in all psychiatric facilities, and as such, screening using serum markers will likely complement clinical examination-guided autoantibody testing in the future.
Dr. Guasp et al. assessed the performance of serum neurofilament light chain (NfL) testing in differentiating anti-NMDA receptor encephalitis (NMDARe) from psychiatric causes of a first episode of psychosis (pFEP) in an observational study of 118 patients with NMDARe (33 of whom had isolated psychosis at presentation), comparing them with 45 patients with pFEP, 36 patients with herpes simplex encephalitis (HSV), and 36 healthy controls. They found that young patients with first episode psychosis and serum NfL ≥15 pg/mL had a 120 times higher chance of having NMDARe than pFEP, with this cutoff correctly classifying 96% of patients with pFEP and 85% of patients with NMDARe and isolated psychosis. Notably, all patients with HSV also had serum NFL≥15 pg/mL. The authors concluded that patients with first episodes of psychosis of unclear etiology and serum NfL ≥15 pg/mL should undergo testing for NMDAR antibodies in the CSF. In response, Dr. Vale notes that the presence of NMDAR antibodies is not essential for diagnosing autoimmune encephalitis, given that other autoantibodies can cause psychotic presentations, and that elevations of NfL may reflect comorbidities causing central or peripheral neuroaxonal damage. Dr. Vale argues that given the severity of first episodes of psychosis, all such patients should be considered for CSF examinations, as was the historical practice for concerns of neurosyphilis. Responding to these comments, the authors agree that CSF studies should be reincorporated in the evaluation of patients with new onset psychosis, but note that they restricted their study to the identification of NMDARe, given that this condition can almost perfectly mimic psychiatric causes of first episodes of psychosis, in contrast to other autoimmune encephalitides, which typically have other concurrent neurologic features. They argue that the usefulness of serum NfL testing seen in their study is a relevant finding, regardless of any other underlying contributors to NfL elevation. This exchange highlights the importance of ongoing research into noninvasive markers of neurologic causes of psychosis. It is the editors' opinion that in practice, routine CSF testing for all patients with first episodes of psychosis is unlikely to be feasible in all psychiatric facilities, and as such, screening using serum markers will likely complement clinical examination-guided autoantibody testing in the future.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- Received July 15, 2022.
- Accepted in final form July 15, 2022.
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
